Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity

Vaccine

Volumn 27, Issue SUPPL.6, 2009, Pages

  Prchal, Michaela ^c,d   Pilz, Andreas ^a,d   Simma, Olivia ^a,d   Lingnau, Karen ^b,d   von Gabain, Alexander ^b,d   Strobl, Birgit ^c,d   Müller, Mathias ^c,d   Decker, Thomas ^a,d  

^a UNIVERSITY OF VIENNA   (Austria)

^b INTERCELL AG   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Dendritic cell; Immune adjuvant; Interferon; T lymphocyte

Indexed keywords

ALPHA INTERFERON; FREUND ADJUVANT; INTERFERON; TOLL LIKE RECEPTOR 9; VACCINE;

ADJUVANT THERAPY; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; INNATE IMMUNITY; MEDIATOR; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DRUG COMBINATIONS; FREUND'S ADJUVANT; INTERFERON TYPE I; MICE; OLIGODEOXYRIBONUCLEOTIDES; OLIGOPEPTIDES; T-LYMPHOCYTES; VACCINES;

EID: 72049114952     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.016     Document Type: Article

References (45)

1. Isaacs A., and Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147 (1957) 258-267
2. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202 (2004) 8-32
3. Schroder K., Hertzog P.J., Ravasi T., and Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75 (2004) 163-189
4. Ank N., and Paludan S.R. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 35 (2009) 82-87
5. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002) 651-662
6. Schindler C., Levy D.E., and Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282 (2007) 20059-20063
7. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6 (2007) 975-990
8. Sen G.C., and Sarkar S.N. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr Top Microbiol Immunol 316 (2007) 233-250
9. Sarkar S.N., and Sen G.C. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol Ther 103 (2004) 245-259
10. Sen G.C. Viruses and interferons. Annu Rev Microbiol 55 (2001) 255-281
11. Weber F., and Haller O. Viral suppression of the interferon system. Biochimie 89 (2007) 836-842
12. Zhang S.Y., Boisson-Dupuis S., Chapgier A., Yang K., Bustamante J., Puel A., et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 226 (2008) 29-40
13. Pichlmair A., and Reis e Sousa C. Innate recognition of viruses. Immunity 27 (2007) 370-383
14. Honda K., and Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6 (2006) 644-658
15. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511
16. Panne D. The enhanceosome. Curr Opin Struct Biol 18 2 (2008) 236-242
17. Ishii K.J., and Akira S. Potential link between the immune system and metabolism of nucleic acids. Curr Opin Immunol 20 (2008) 524-529
18. Ishii K.J., and Akira S. Innate immune recognition of nucleic acids: beyond toll-like receptors. Int J Cancer 117 (2005) 517-523
19. Barchet W., Cella M., and Colonna M. Plasmacytoid dendritic cells-virus experts of innate immunity. Semin Immunol 17 (2005) 253-261
20. Gilliet M., Cao W., and Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8 (2008) 594-606
21. Havenar-Daughton C., Kolumam G.A., and Murali-Krishna K. Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176 (2006) 3315-3319
22. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., and Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202 (2005) 637-650
23. Thompson L.J., Kolumam G.A., Thomas S., and Murali-Krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 177 (2006) 1746-1754
24. Aichele P., Unsoeld H., Koschella M., Schweier O., Kalinke U., and Vucikuja S. CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol 176 (2006) 4525-4529
25. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
26. Le Bon A., Durand V., Kamphuis E., Thompson C., Bulfone-Paus S., Rossmann C., et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176 (2006) 4682-4689
27. Le Bon A., Thompson C., Kamphuis E., Durand V., Rossmann C., Kalinke U., et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176 (2006) 2074-2078
28. Bach P., Kamphuis E., Odermatt B., Sutter G., Buchholz C.J., and Kalinke U. Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol 178 (2007) 5839-5847
29. Curtsinger J.M., Valenzuela J.O., Agarwal P., Lins D., and Mescher M.F. Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174 (2005) 4465-4469
30. Freudenberg M.A., Merlin T., Kalis C., Chvatchko Y., Stubig H., and Galanos C. Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by Type I IFN and IL-18 signaling. J Immunol 169 (2002) 1665-1668
31. Nguyen K.B., Watford W.T., Salomon R., Hofmann S.R., Pien G.C., Morinobu A., et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297 (2002) 2063-2066
32. Le Bon A., Etchart N., Rossmann C., Ashton M., Hou S., Gewert D., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4 (2003) 1009-1015
33. Le Bon A., and Tough D.F. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev 19 (2008) 33-40
34. Tovey M.G., Lallemand C., and Thyphronitis G. Adjuvant activity of type I interferons. Biol Chem 389 (2008) 541-545
35. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169 (2002) 375-383
36. Bracci L., Canini I., Puzelli S., Sestili P., Venditti M., Spada M., et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23 (2005) 2994-3004
37. Tovey M.G., Lallemand C., Meritet J.F., and Maury C. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 24 Suppl 2 (2006) S2-46-7
38. Rizza P., Capone I., Urbani F., Montefiore E., Rapicetta M., Chionne P., et al. Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine 26 (2008) 1038-1049
39. Grob P.J., Jollerjemelka H.I., Binswanger U., Zaruba K., Descoeudres C., and Fernex M. Interferon as an adjuvant for Hepatitis-B Vaccination in non-responder and low-responder populations. Eur J Clin Microbiol Infect Dis 3 (1984) 195-198
40. Goldwater P.N. Randomized comparative trial of interferon-alpha versus placebo in Hepatitis-B vaccine nonresponders and hyporesponders. Vaccine 12 (1994) 410-414
41. Launay O., Grabar S., Bloch F., Desaint C., Jegou D., Lallemand C., et al. Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 26 (2008) 4073-4079
42. Couch R.B., Atmar R.L., Cate T.R., Quarles J.M., Keitel W.A., Arden N.H., et al. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine 27 (2009) 5344-5348
43. Haller O., Stertz S., and Kochs G. The Mx GTPase family of interferon-induced antiviral proteins. Microbes Infect 9 (2007) 1636-1643
44. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24 (2006) 5461-5472
45. Pilz A., Kratky W., Stockinger S., Simma O., Kalinke U., Lingnau K., et al. Dendritic cells require Stat1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol 183 (2009) 2286-2293